STEPHEN KANOVSKY

Corporate Board Profile

Tech Score: 0/100

NEOGENOMICS INC

Filing Date	Source Excerpt
2023-04-07	Stephen Kanovsky, age 60, Board Member and Chair of the Nominating and Corporate Governance Committee. Mr. Kanovsky has served as a director since July 2017. The Board currently has four standing committees: the Audit and Finance Committee, the Compliance Committee, the Culture and Compensation Committee, and the Nominating and Corporate Governance Committee. Stephen Kanovsky serves on the Nominating and Corporate Governance Committee as Chair. The following table provides the compensation of each of our independent directors for the year ended December 31, 2022. Mr. Kanovsky received total compensation of $245,000.
2024-04-08	Mr. Kanovsky has served as a director since July 2017. Mr. Kanovsky is Deputy General Counsel and Chief Commercial Counsel of GE HealthCare, where he has served since 2012, which provides medical technologies and solutions to the global healthcare industry and supports customers throughout the world with a broad range of services and systems, from diagnostic imaging and healthcare IT to molecular diagnostics and life sciences. Prior to his service at GE HealthCare, Mr. Kanovsky held numerous legal, compliance, and research roles in several global pharmaceutical companies. Mr. Kanovsky earned his bachelor’s degree from the University of Pennsylvania. He subsequently graduated from Temple University’s School of Pharmacy with a master’s degree in Pharmacology and Temple University’s School of Law with a juris doctorate degree. Mr. Kanovsky also holds an MBA from Saint Joseph’s University’s Haub School of Business. For service as a director during 2023, independent directors received total annual equity compensation having a grant date fair value of $240,000. For service as a director during 2023, each independent director received annual compensation of $50,000. Directors serving as Audit and Finance Committee members received annual compensation of $10,000. Directors serving as Nominating and Corporate Governance Committee members received annual compensation of $5,000.

Filing Date

Source Excerpt

2023-04-07

Stephen Kanovsky, age 60, Board Member and Chair of the Nominating and Corporate Governance Committee. Mr. Kanovsky has served as a director since July 2017. The Board currently has four standing committees: the Audit and Finance Committee, the Compliance Committee, the Culture and Compensation Committee, and the Nominating and Corporate Governance Committee. Stephen Kanovsky serves on the Nominating and Corporate Governance Committee as Chair. The following table provides the compensation of each of our independent directors for the year ended December 31, 2022. Mr. Kanovsky received total compensation of $245,000.

2024-04-08

Mr. Kanovsky has served as a director since July 2017. Mr. Kanovsky is Deputy General Counsel and Chief Commercial Counsel of GE HealthCare, where he has served since 2012, which provides medical technologies and solutions to the global healthcare industry and supports customers throughout the world with a broad range of services and systems, from diagnostic imaging and healthcare IT to molecular diagnostics and life sciences. Prior to his service at GE HealthCare, Mr. Kanovsky held numerous legal, compliance, and research roles in several global pharmaceutical companies. Mr. Kanovsky earned his bachelor’s degree from the University of Pennsylvania. He subsequently graduated from Temple University’s School of Pharmacy with a master’s degree in Pharmacology and Temple University’s School of Law with a juris doctorate degree. Mr. Kanovsky also holds an MBA from Saint Joseph’s University’s Haub School of Business. For service as a director during 2023, independent directors received total annual equity compensation having a grant date fair value of $240,000. For service as a director during 2023, each independent director received annual compensation of $50,000. Directors serving as Audit and Finance Committee members received annual compensation of $10,000. Directors serving as Nominating and Corporate Governance Committee members received annual compensation of $5,000.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-19